AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04164147 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: one of the Persona MC Retained PCL, Persona MC Sacrificed PCL and NexGen PS total knee implant
Description: Participant are randomly allocated to receive one of the Persona MC Retained PCL, Persona MC Sacrificed PCL and the NexGen PS total knee implant for treatment of end-stage knee osteoarthritis.
Study NCT01217918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 mg
Description: 1 mg or placebo a material sparing tablet per day for 10 days
Study NCT01217918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 mg
Description: 5 mg or placebo as material sparing tablet per day for 10 days
Study NCT01101269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACEI or ARB
Description: Subjects will be asked to discontinue their usual ACE inhibitor or Angiotensin Receptor Blocker (ARB) for ten days, undergo a CEU using Definity (for renal blood flow assessment) as the contrast agent, then resume their usual ACEI or ARB for ten days, then undergo another CEU using Definity as the contrast agent.
Study NCT01101269 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lisinopril
Description: Subjects will be undergo a CEU using Definity (for renal blood flow assessment) as the contrast agent, then take Lisinopril 10 mg every day for 7 days, after which they will undergo another CEU using Definity as the contrast agent.
Study NCT01852669 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Inversion
Description: Patients inverted 30 degree head down in Trendelenburg position
Study NCT01852669 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Shock Wave Lithotripsy
Description: Shock wave lithotripsy
Study NCT01217918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg
Description: 10 mg or placebo as a material sparing tablet per day for 10 days
Study NCT03491150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crenezumab
Description: Crenezumab was administered by intravenous (IV) infusion at 60mg/kg as per the dosing schedule described above.
Study NCT03491150 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Crenezumab
Description: Crenezumab was administered by intravenous (IV) infusion at 60mg/kg as per the dosing schedule described above.
Study NCT01110629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosrenol (Lanthanum Carbonate, BAY77-1931)
Description: Daily dose: 750-2250mg 3 times a dayfor 8 weeks.
Study NCT01110629 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: daily dose: 3 tablets TID for 8 weeks.
Study NCT01211028 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Expanded autologous ASCs
Description: Drug: Expanded autologous adipose-derived adult stroma/stem cells
Study NCT01245855 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: lipo-PGE1
Description: those in the PGE1 group received additional 20 micrograms/day of lipo-PGE1 intravenously, starting at least 24 hours before PCI and continuing for 5 days
Study NCT02539875 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AWARD and brief leaflet/ Referral leaflet and active referral/ Smoking cessation booklet and general advices
Description: Use AWARD and brief leaflet/ Referral leaflet and active referral/ Smoking cessation booklet and general advices interventions to achieve smoking abstinence
Study NCT02539875 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: AWARD and brief leaflet/ Referral leaflet and active referral/ Smoking cessation booklet and general advices
Description: Use AWARD and brief leaflet/ Referral leaflet and active referral/ Smoking cessation booklet and general advices interventions to achieve smoking abstinence
Study NCT01852669 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Shock Wave Lithotripsy
Description: Shock wave lithotripsy
Study NCT01852669 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydration
Description: Hydration of patient with 0.5L NaCl and 20mg frusemide IV
Study NCT02456831 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Infant Formula 1
Description: method A phytate reduction and 5% protein hydrolysis
Study NCT02456831 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Infant Formula 2
Description: method A phytate reduction and 10% protein hydrolysis
Study NCT02456831 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Infant Formula 3
Description: method B phytate reduction and 5% protein hydrolysis
Study NCT02456831 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Control Infant Formula
Description: Ready-to-Feed (RTF) Soy Infant Formula
Study NCT03915288 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group continuous training at moderate intensity
Description: 70 minutes for intervention, where 10 minutes were warm up (breathing exercises, walking, stretching), 30 minutes of continuous aerobic training at moderate intensity (60-80% FCM), with fast walking or endless tread with the floor inclined to reach the desired intensity. Also on bicycle, rowing and elliptical; Then, 20 minutes of strength training (40-60% maximum strength) with dumbbells and theraban. Ends with 10 minutes of cooling with walking and breathing exercises.
Study NCT03915288 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group high Intensity Interval Training
Description: 70 minutes for intervention, where 10 minutes were for warm-up (Respiratory exercises, walking, stretching), 30 minutes consisted of an intensity of interval training. That is, the participants who underwent 30 minutes of aerobic exercise consisted of a protocol created for this experimental group that we named 30-30. 30 seconds at moderate intensity (60-80% FCM) and 30 seconds at high intensity (80-90%). ; Then, 20 minutes of strength training (40-60% maximum strength) with dumbbells and theraban. Ends with 10 minutes of cooling with walking and breathing exercises.
Study NCT03915288 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group control
Description: This group did not perform supervised exercise nor were they given exercise recipes or formal intervention programs. Only continued with the usual care and gave directions to maintain a healthy lifestyle based on proper nutrition and usual activities.
Study NCT01552538 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cyberonics VNS System
Description: Stimulation with an active implantable electrical vagal nerve stimulation device
Study NCT01852669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydration
Description: Hydration of patient with 0.5L NaCl and 20mg frusemide IV
Study NCT04854421 — intervention group
Intervention type: DEVICE
Intervention: VBC
Description: Body Composition will be measured using the VBC system that takes under 60 seconds per scan. Image capture for VBC will include taking a series of four photos using a smartphone camera. Data from the camera will be downloaded to a local computer and then securely sent to the cloud for automated analysis and results generation. We will conduct two consecutive scans (image captures) for each research participant.
Study NCT01785251 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular Electrical Stimulation
Description: Applied using a custom built, medically approved stimulator called the Duo-STIM. NMES to be applied to the calf muscles to elicit a muscular contraction to eject blood through the venous system.
Study NCT02760849 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02760849 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02760849 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oophorectomy
Description: Undergo ISDO
Study NCT02760849 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02760849 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02760849 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Salpingectomy
Description: Undergo ISDO
Study NCT02760849 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Salpingo-Oophorectomy
Description: Undergo RRSO
Study NCT03054675 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Spirometry
Description: Absolute FEV1 is measured in every patient using a handheld spirometer
Study NCT03518008 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: somofilcon A contact lenses
Description: Commercially available daily disposable soft contact lenses
Study NCT00472004 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 17B Estradiol (1mg) / (0.125 mg) TMG Continuous combined (Totelle)
Description: 17B Estradiol (1mg) / (0.125 mg) TMG Continuous combined, 1 Daily, 1 year duration
Study NCT01296516 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Non-intervention group
Description: A pedometer and written material on a healthy lifestyle.
Study NCT01296516 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Face to face
Description: Motivational meetings held once per week; Behavioral sessions weill be led by a trained interventionist.
Study NCT01296516 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telehelath Group
Description: Participants will speak to Trestletree personnel once a week via phone.
Study NCT01150214 — intervention group
Intervention type: PROCEDURE
Intervention: DE-MRI
Description: Using Delayed-Enhancement Magnetic Resonance Imaging (DE-MRI) to identify fibrotic and scarred cardiac tissue. DE-MRI is a non-invasive method of identifying the extent and the distribution of structural remodeling or fibrosis and scarring associated with atrial fibrillation both pre- and post-ablation.
Study NCT01289925 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Selenium
Description: 200 micrograms of selenium (in the form of selenium methionine) in tablet form taken orally daily for 8 weeks. Capsule molds with inert coating.
Study NCT01289925 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill Placebo
Description: Placebo supplements in the same capsule mold as selenium and coated with the same inert coating. 1 tablet daily for 8 weeks.
Study NCT03086785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: apatinib 500mg qd po or combined capecitabine 1000mg/m2 bid d1-14 q3w
Study NCT05005858 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Alveolar ridge splitting
Description: Patients with Kennedy Class I. and II. mandibles with insufficient bone width were included in this study. Ridge splitting was carried out with the use of a piezoelectric surgery device by preparing osteotomies and after mobilization of the buccal cortical by placing an autologous bone block harvested from the retromolar region as a spacer between the buccal and lingual cortical plates. Block-grafts were stabilized by osteosynthesis screws. Implant placement was carried out after a 3-month healing period.
Study NCT05005858 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Creating osteotomies with piezoelectric device
Description: Osteotomies were carried out with piezoelectric surgery device (NSK Variosurg3 Ultrasonic Bone Surgery System, NSK Europe GmbH, Eschborn, Germany)
Study NCT02479854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asmakast
Description: 1 chewable tablet contains 5 mg montelukast
Study NCT02479854 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Singulair
Description: 1 chewable tablet contains 5 mg montelukast
Study NCT00472004 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tibolone (Livial)
Description: Tibolone 2.5 mg 1 daily, 1 year duration
Study NCT01232764 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exposure to multi-disciplinary wound care team
Description: Phase 1: In Person Support (3 mths)~Advance Practice Nurses (APNs) affiliated with Enhanced Multi-Disciplinary visit LTC facilities on a weekly basis. The APN may communicate with other members of an EMDT via telephone or online.EMDTs will collectively teach and mentor LTC facility wound care teams throughout the study.~Phase 2: Remote Support (2-11 mths) In the second phase, EMDTs will support LTC facility staff remotely via telephone and online communication, visiting the facilities on an as needed basis only.~All PU treatment will be based on RNAO evidence-based guidelines (updated in 2007)contextualized to the LTC setting.
Study NCT01656850 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Almond diet first, then NCEP Diet
Description: whole almonds will be incorporated into a control diet which is a NCEP step 2 diet. Whole almonds will replace 20% daily calorie intake. Subjects were assigned to receive almond diet for 12 weeks after a 2-weeks run-in period. After washout 2 weeks, change diet to NCEP Diet for 12 weeks
Study NCT01656850 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NCEP diet first, then Almond diet
Description: NCEP diet first, then Almond diet. Subjects were assigned to receive NCEP diet for 12 weeks after a 2-weeks run-in period. After washout 2 weeks, change diet to almond diet for 12 weeks
Study NCT00325234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 600 mg/m\^2, administered intravenously (IV) every 21 days until disease progression or unacceptable toxicity.
Study NCT00325234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 5 mg\*min/mL, administered IV every 21 days until disease progression or unacceptable toxicity.
Study NCT00325234 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: 1200 mg/m\^2 gemcitabine, administered IV on day 1 and day 8 every 21 days until disease progression or unacceptable toxicity.
Study NCT00325234 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine
Description: 30 mg/m\^2 vinorelbine administered IV on day 1 and day 8 every 21 days until disease progression or unacceptable toxicity.
Study NCT00461539 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Those participants receiving standard care will be referred to special programs as needed to reduce their involvement in risky health behaviors.
Study NCT00461539 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral health intervention
Description: Participants assigned to the health education intervention will attend 10 weekly education sessions that will be led by trained health educators. Parents or guardians may be asked to attend sessions depending on their interest in the intervention and the age of the youth participant. Topics covered will include teenage smoking, alcohol and drug abuse, risky sexual behaviors, and obesity. Cognitive-behavioral strategies, role playing, and media clips will be used to stimulate discussion and involvement in the intervention.
Study NCT01888289 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotretinoin
Description: Isotretinoin Capsules,40 mg
Study NCT01888289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin
Description: Isotretinoin Capsules,40 mg
Study NCT02402452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voxilaprevir
Description: 100 mg tablet administered orally
Study NCT01389440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine and Erlotinib
Description: Administration of gemcitabine (300mg/m2/weekly)with Erlotinib (100 mg/daily) and radiotherapy (45 Gy/daily) after a period of infusion with a full dose of Gemcitabine (1.000mg/m2/weekly) and Erlotinib (100 mg/daily)
Study NCT04277988 — intervention group
Intervention type: DEVICE
Intervention: Ultrasonography
Description: Length of Posterior Longitudianl Ligament, Ligamentum Flavum and Interlaminar distance visible in paramedian longitudinal view during lumbar spine ultrasonography in cross legged position will be compared to standard sitting position.
Study NCT00792610 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hepatitis B vaccine
Description: Recombinant HBsAg, 20mcg/ml/vial (GSK) one vial IM at Day 0, Month 1, month 6 during follow-up, respectively.
Study NCT02059148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2835219
Description: Administered orally.
Study NCT00691236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: 4mg IV 3 weekly for 6 doses
Study NCT00691236 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard chemotherapy
Description: Adriamycin + Cisplatinum and Ifosfamide
Study NCT00691236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard chemotherapy
Description: Adriamycin + Cisplatinum and Ifosfamide
Study NCT05355506 — intervention group
Intervention type: DEVICE
Intervention: Application
Description: Knowledge \& record
Study NCT03397576 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ATHENA
Description: Adherence Through Home Education and Nursing Assessment (ATHENA), is an evidence-based ART adherence intervention delivered in the patient's home by nurses and peer educators working in teams.
Study NCT00323830 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine, cisplatin, Radiotherapy (+/-)
Description: Capecitabine, cisplatin + Radiotherapy (randomized)
Study NCT00323830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine, cisplatin, Radiotherapy (+/-)
Description: Capecitabine, cisplatin + Radiotherapy (randomized)
Study NCT04163393 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention
Description: PCI with robotic assistance
Study NCT04163393 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention using R-One assistance
Description: PCI with robotic assistance
Study NCT00811564 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution
Description: 1 drop of study medication taken approximately 12 hours apart, dosed 2 times a day
Study NCT00811564 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: latanoprost 0.005%
Description: 1 drop of study medication taken once daily
Study NCT01862172 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Additional MRI
Study NCT04619706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FSD201
Description: Tablets for oral administration.
Study NCT04619706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets matched to FSD201 for oral administration.
Study NCT04619706 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets matched to FSD201 for oral administration.
Study NCT04619706 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care for Covid-19
Description: Standard of care for Covid-19 as determined by site PI
Study NCT04036981 — intervention group
Intervention type: DRUG
Intervention: Botulinum toxin type A
Description: Injection of botulinum toxin A into the spastic elbow flexor muscle or muscles
Study NCT04619706 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care for Covid-19
Description: Standard of care for Covid-19 as determined by site PI
Study NCT00003196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy
Description: Undergo cytoreductive chemotherapy
Study NCT00003196 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Description: Undergo TBI
Study NCT02266355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: Omalizumab 300 mg SQ every 2 weeks
Study NCT02946034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Viekira Pak ± ribavirin
Description: 12 weeks treatment with AbbVie Viekira Pak ± ribavirin
Study NCT00003196 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Undergo allogeneic PBSC transplant
Study NCT00003196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Given IV or PO
Study NCT02946034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mavyret
Description: 8 or 12 weeks treatment with AbbVie Mavyret
Study NCT00507013 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: QuickClose device
Study NCT00003196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: Given PO
Study NCT00003196 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Description: Undergo allogeneic PBSC transplant
Study NCT00003196 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic allogeneic lymphocytes
Description: Undergo DLI
Study NCT02362724 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sapphire
Description: silicone hydrogel contact lens
Study NCT02362724 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pearl
Description: silicone hydrogel contact lens
Study NCT04863391 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Referrable versus Non Referral AMD diagnostic test
Description: Artificial intelligence read reports Referrable versus Non Referral AMD